Rewards
Some stock data isn't available right now.

Savara Inc. (SVRA)

Underlying price

$4.29

-17.58% last session

Stock stats

$939M
$5.21
$4.19
$3.50 – $5.42
$4.00 – $7.00
16.5M
2.81M
-
0.408
-$0.6
-
0.388

Analysts & earnings

Analyst ratings

Buy, 4.33 on a scale from 1, strong sell, to 5, strong buy
  • 3 Strong buy
  • 6 Buy
  • 0 Hold
  • 0 Sell
  • 0 Strong sell
$10.83+152.21%
Today
$4.29
Target
$10.83

Earnings per share

Beat estimates 1 of last 4

  • Estimate
  • Actual
  • Mar '26: actual -$0.13, estimate -$0.12
  • May '26: actual -$0.1472, estimate -$0.1183
  • Aug '26: actual -$0.16, estimate -$0.14
  • Nov '26: actual -$0.17, estimate -$0.18

About Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Ticker
SVRA
Asset class
Equity
Tokenized by
0 issuers
Sector
Healthcare
Industry
Pharmaceutical Preparations
Employees
70